Responses to imatinib mesylate therapy
| Type of response . | No. of patients (%) . | ||
|---|---|---|---|
| Total . | Blast type . | ||
| Nonlymphoid . | Lymphoid . | ||
| Total treated | 75 | 65 | 10 |
| CHR | |||
| Total | 16 (21) | 15 (23) | 1 (10) |
| Cytogenetic response | 8 (11) | 7 (11) | 1 (10) |
| Minor | 2 (3) | 2 (3) | |
| Partial | 2 (3) | 2 (3) | |
| Complete | 4 (6) | 3 (5) | 1 (10) |
| HI | |||
| Total | 12 (16) | 11 (17) | 1 (10) |
| Cytogenetic response | 4 (5) | 4 (6) | |
| Minor | 2 (3) | 4 (6) | |
| Partial | 1 (1) | 1 (2) | |
| Complete | 1 (1) | 1 (2) | |
| PHR | 3 (4) | 3 (5) | |
| Second chronic phase | 7 (9) | 6 (8) | 1 (10) |
| Early death | 2 (3) | 2 (3) | |
| Aplastic death | 0 | 0 | 0 |
| Resistance disease | 21 (28) | 18 (28) | 3 (30) |
| Inevaluable | 5 | 3 | 2 |
| Complete/partial marrow response | 2 + 5 (9) | 2 + 4 (9) | 0 + 1 (10) |
| Imatinib mesylate response criteria met by patient13 | |||
| Marrow CR + recovery (ie, CHR) | 16 (21) | 15 (23) | 1 (10) |
| Marrow CR, no recovery | 20 (27) | 19 (29) | 1 (10) |
| Marrow PR | 8 (11) | 6 (9) | 2 (20) |
| Type of response . | No. of patients (%) . | ||
|---|---|---|---|
| Total . | Blast type . | ||
| Nonlymphoid . | Lymphoid . | ||
| Total treated | 75 | 65 | 10 |
| CHR | |||
| Total | 16 (21) | 15 (23) | 1 (10) |
| Cytogenetic response | 8 (11) | 7 (11) | 1 (10) |
| Minor | 2 (3) | 2 (3) | |
| Partial | 2 (3) | 2 (3) | |
| Complete | 4 (6) | 3 (5) | 1 (10) |
| HI | |||
| Total | 12 (16) | 11 (17) | 1 (10) |
| Cytogenetic response | 4 (5) | 4 (6) | |
| Minor | 2 (3) | 4 (6) | |
| Partial | 1 (1) | 1 (2) | |
| Complete | 1 (1) | 1 (2) | |
| PHR | 3 (4) | 3 (5) | |
| Second chronic phase | 7 (9) | 6 (8) | 1 (10) |
| Early death | 2 (3) | 2 (3) | |
| Aplastic death | 0 | 0 | 0 |
| Resistance disease | 21 (28) | 18 (28) | 3 (30) |
| Inevaluable | 5 | 3 | 2 |
| Complete/partial marrow response | 2 + 5 (9) | 2 + 4 (9) | 0 + 1 (10) |
| Imatinib mesylate response criteria met by patient13 | |||
| Marrow CR + recovery (ie, CHR) | 16 (21) | 15 (23) | 1 (10) |
| Marrow CR, no recovery | 20 (27) | 19 (29) | 1 (10) |
| Marrow PR | 8 (11) | 6 (9) | 2 (20) |
Data are given as number (%) of patients. CHR indicates complete hematologic response; HI, hematologic improvement; PHR, partial hematologic response; CR, complete response; PR, partial response.